Radiopharmaceuticals are the next frontier in oncology, but the current generation of products is barely scratching the surface of this massive opportunity. From rolling out into new indications and diseases to combination therapies, the possibilities are endless. Driven by strong efficacy and safety data, its proprietary platform technology and numerous supply and manufacturing benefits enabled by copper isotopes, Clarity is well positioned to roll out its pipeline of radiopharmaceuticals and meet the demand for better treatments.
Watch season 2 episode 5 below, featuring Clarity’s Executive Chairperson, Dr Alan Taylor, and Wilsons Advisory's Deputy Head of Research, Melissa Benson, to learn about the future of radiopharmaceuticals and emerging trends in the field.
Click on the following link to watch previous episodes of the Science Hat podcast and learn more about Clarity’s TCT platforms: www.claritypha...
Негізгі бет The Science Hat Podcast - Season 2 Episode 6 - If you are not in radiopharm, you are not serious
Пікірлер